this is exactly the problem..you cannot dramatically change the board make up and management and expect everything to go seamlessly. Far from it. anything in process will have to be re-calibrated from a delivery standpoint with new players taking the lead on all the projects. and you can forget the sales pitch from 13 D on how the FDA and their team are more friendly. that doesnt mean squat and is pandering expecting retail investors to believe that miraculouly, trials will speed up and approvals are just there waiting